Axsome Therapeutics, Inc. (AXSM) is a pioneering biopharmaceutical company focused on developing and delivering innovative therapies in the healthcare space, primarily targeted towards central nervous system (CNS) disorders.
Founded in 2012 and headquartered in New York City, Axsome Therapeutics operates with the mission to create distinctive therapies that improve quality of life for patients grappling with limited treatment options. These include individuals struggling with conditions such as major depressive disorder, Alzheimer's disease, treatment-resistant depression, migraine, and agitation associated with Alzheimer's disease.
The company lays heavy emphasis on the development of a robust and diversified product line-up that encompasses novel medicines with technology-driven delivery systems. To bring their vision to life, Axsome Therapeutics is backed by a team of highly skilled scientists and industry professionals who are committed to a strategic approach in research, development, and commercialization of potentially life-changing pharmaceuticals.
As of now, Axsome Therapeutics has several leading products in various stages of clinical development. Two of its leading CNS product candidates are AXS-05 and AXS-07. AXS-05 is being developed for major depressive disorder and treatment-resistant depression, among others, and AXS-07 is being developed for treating acute migraine. Both these drugs have exhibited strong potential and encouraging results in their respective clinical trials.
In addition to these, the company has a rich pipeline of promising product candidates like AXS-12 and AXS-14. AXS-12 is targeted to treat narcolepsy, and AXS-14 is for chronic pain associated with osteoarthritis of the knee.
The successful advancements and potential of its leading products have significantly contributed to Axsome Therapuetics' impressive performance in the stock market. The company is publically traded on the NASDAQ under the symbol “AXSM”.
Though the company is relatively young, it is aggressively moving forward in its pursuit to deliver next-generation CNS medicines. Axsome Therapeutics' relentless dedication, emphasis on innovation, and the high potential of its clinical candidates are making it a company to watch in the biopharmaceutical arena.
Lastly, Axsome is more than just a corporation; it’s a team devotedly pushing the boundaries of CNS treatments. The company's work has the potential to significantly better the lives of patients and families affected by these life-altering disorders and diseases. In doing so, Axsome Therapeutics is not only advancing medical science but making a meaningful difference in the global community.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Axsome Therapeutics reported a third-quarter 2026 net loss of $12.9 million, or $0.25 per share, which was better than analyst expectations of a $0.69 loss per share. The company's revenue reached $259.7 million, exceeding the average analyst estimate of $246.4 million. Despite a 21% decline in shares since the beginning of 2026, Axsome gained 7% over the past 12 months.
Axsome Therapeutics announced strong financial results for the third quarter of 2026, with total net product revenue reaching $259.7 million, a 52% year-over-year increase. Key products like AUVELITY, SUNOSI, and SYMBRAVO all demonstrated significant sales growth, contributing to the company surpassing a one-billion-dollar annual run rate. Additionally, Axsome provided updates on its neuroscience pipeline, highlighting the initiation of the SUMMIT Phase 3 trial for AXS-05 for smoking cessation and anticipated milestones for several other drug candidates.
Washington Trust Advisors Inc. significantly increased its stake in Axsome Therapeutics (NASDAQ:AXSM) by over 25,000% during the third quarter, now holding 43,963 shares valued at approximately $8.1 million. This comes as Axsome shares have fallen to $145.04, below their moving averages, and the company reported a quarterly loss and revenue miss. Despite insider selling by the CEO and COO totaling around $12.6 million, analysts maintain a "Moderate Buy" consensus with an average price target of $275.74.
Assenagon Asset Management S.A. significantly reduced its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by selling 203,877 shares in the third quarter, retaining 250,805 shares valued at $46.2 million. This comes as Axsome Therapeutics reported a quarterly loss of $0.99 per share and revenue of $218.4 million, both missing analyst estimates. Despite mixed financial results and insider selling, analysts maintain a "Moderate Buy" rating with a consensus price target of $275.74.
Axsome Therapeutics (AXSM) has seen a significant 296.3% gain over the past five years, but its current valuation suggests it might be trading at a discount. Despite trading at a P/S ratio of 10.9x, which is higher than the industry average, Simply Wall St's analysis and community narratives suggest the stock could be undervalued by as much as 43% when considering its growth potential, profitability, and risk profile. Investors are encouraged to examine analyst forecasts for future performance before making investment decisions.
Axsome Therapeutics (NASDAQ:AXSM) shares increased by 4.4% on Wednesday, despite a significant drop in trading volume. The company holds a "Moderate Buy" consensus rating from analysts with an average price target of $275.74, and institutional investors own 81.49% of its shares. However, the company missed recent quarterly EPS and revenue estimates, and insiders have sold approximately $12.6 million worth of stock in the last 90 days.